Clinical Trial Update: Safety, Tolerability and Pharmacokinetics of a Recombinant Humanized mAb Specific to B-and T-Lymphocyte Attenuator (BTLA) for Injection in Subjects With Advanced Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability and pharmacokinetics of a recombinant humanized anti-BTLA monoclonal antibody in patients with advanced solid tumo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• BTLA monoclonal antibody (anti-BTLA monoclonal antibody)

Snippet

Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Conditions: Advanced Solid Tumor | Phase 1 | Status: COMPLETED